Autonomix Medical spotlights pancreatic cancer pain feasibility data at surgical oncology meeting

Autonomix Medical, Inc.

Autonomix Medical, Inc.

AMIX

0.00
  • Autonomix Medical highlighted clinical data on visceral cancer pain management that were already presented at the Society of Surgical Oncology annual meeting.
  • A City of Hope physician said the pancreatic cancer feasibility results support continued clinical development of the company’s nerve-targeted device platform.
  • The discussion pointed to potential use beyond pancreatic cancer, positioning the technology as a broader peripheral nervous system treatment approach.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autonomix Medical Inc. published the original content used to generate this news brief on June 04, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.